<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093103</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00099</org_study_id>
    <nct_id>NCT03093103</nct_id>
  </id_info>
  <brief_title>Empagliflozin and Renal Oxygenation in Healthy Volunteers</brief_title>
  <acronym>EMPA-REIN</acronym>
  <official_title>Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SGLT-2 inhibitors belong to a new class of hypoglycemic drugs with the unique property of
      decreasing blood glucose through an increase in glucosuria. These drugs inhibit the sodium
      glucose transporter 2 (SGLT2) expressed at the luminal membrane of the proximal tubule.

      SGLT-2 inhibition in type 2 diabetic subjects and in healthy volunteers shifts the threshold
      for renal glucose excretion to lower levels. This effect is independent from insulin. The
      inhibition of SGLT2 decreases HbA1C, systolic blood pressure and weight in diabetic subjects.
      Recently, the EMPA-REG trial demonstrated a decrease in cardiovascular mortality and renal
      endpoints in empagliflozin treated type 2 diabetic patients with established cardio-vascular
      disease.

      Because this novel hypoglycemic drug has unique and direct effects on renal tissue
      metabolism, it is important to better examine its effects on the kidney. With this study, we
      propose to explore the effects of empagliflozin on renal tissue oxygenation. Our hypothesis
      is that SGLT-2 inhibition decreases renal cortical energy requirements with consequently an
      increase in renal tissue oxygenation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled study that will examine the
      acute and chronic renal effects of empagliflozin in healthy volunteers.

      A total of 45 healthy volunteers will be included in the study: 15 normal weight, 15
      overweight (BMI: 25-30kg/m2) and 15 obese (BMI&gt;30kg/m2) non diabetic subjects (as determined
      after an oral glucose tolerance test).

      Empagliflozin 10mg vs placebo will be administered in a blinded fashion qd. The acute and
      chronic renal response to empagliflozin will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised placebo-controlled double blind trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo and Empagliflozin pills</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Renal oxygenation</measure>
    <time_frame>18 months</time_frame>
    <description>The acute and chronic effect of empagliflozin on renal oxygenation will be assessed by BOLD-MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic effects of empagliflozin on diurnal and nocturnal sodium, potassium, uric acid, calcium, phosphate, glucose and lithium clearances after 4 weeks treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Will be assessed on 24h urinary collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic effects of empagliflozin on renal resistance indexes and renal volume after 4 weeks treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Will be assessed by renal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of empagliflozin on 24h blood pressure mesaurements</measure>
    <time_frame>18 months</time_frame>
    <description>WIll be assessed by ambulatory blood pressure measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of body weight on the renal response to empagliflozin</measure>
    <time_frame>18 months</time_frame>
    <description>Different groups of BMI will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>empagliflozin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken qd for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 mg</intervention_name>
    <description>Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI</description>
    <arm_group_label>empagliflozin 10mg</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal weight (BMI: 19-24.9kg/m2), overweight (BMI:25-30kg/m2) or obesity
             (BMI&gt;30kg/m2)

          -  Men and women (with a negative pregnancy test) during the follicular phase of the
             menstrual cycle. All groups will have a balanced number of men and women.

          -  OGTT/HbA1C: normal or pre-diabetes

          -  eGFR&gt;60ml/min, albumin/creatinine ratio &lt;3.3mg/mmol (&lt;30 mg/g)

          -  Signed consent form

          -  Normal renal ultrasound

          -  Normal urine dipstick

        Exclusion Criteria:

          -  Antihypertensive therapy

          -  NSAID treatment

          -  Former bariatric surgery

          -  Age&lt;18y or &gt;50y

          -  At risk of dehydration or hypotension

          -  Past history of recurrent genital or urinary tract infections

          -  Contra-indication for MR imaging (pacemaker or other implanted metallic device,
             claustrophobia)

          -  Pregnancy

          -  Sustained systolic blood pressure &gt;150mmHg or diastolic blood pressure &gt;95mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Burnier, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Néphrologie CHUV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Burnier, Prof</last_name>
    <phone>+41 21 314 11 54</phone>
    <email>Michel.Burnier@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Zanchi, MD PD</last_name>
    <email>Anne.Zanchi@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guler Gok-sogut, Ass-med</last_name>
      <phone>41 79 556 20 05</phone>
      <email>guler-gok-sogut@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Eve Muller, MD</last_name>
      <phone>41 79 556 59 46</phone>
      <email>Marie-Eve.Muller@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Zanchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Burnier, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Michel Burnier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>empagliflozin</keyword>
  <keyword>kidney</keyword>
  <keyword>BOLD-MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

